CJC-1295 DAC

A cited human study compared pulsatile versus continuous growth hormone delivery and found that pulsatile GH delivery nearly doubled fat breakdown from baseline. Continuous GH delivery showed no difference from doing nothing, indicating that the delivery pattern — not just GH elevation — is critical to achieving body composition benefits.

The speaker argues that running CJC-1295 DAC on a once-weekly schedule is a fundamental protocol error that produces side effects while bypassing the intended mechanism of action. The claim is that users are paying for a protocol that actively works against the pulsatile GH physiology it is meant to support. No specific dosage in mcg or mg is cited.

The speaker warns that chronically elevated IGF-1 levels — a downstream consequence of sustained GH stimulation from CJC-1295 DAC — can contribute to insulin resistance when used without laboratory monitoring. This is framed as a metabolic safety concern specific to the DAC formulation's prolonged action. No specific IGF-1 threshold values or lab testing intervals are mentioned.

The speaker warns that side effects from CJC-1295 DAC — specifically flushing and water retention — cannot be stopped once they occur due to the peptide's extended 6–8 day activity window. Unlike shorter-acting formulations, there is no ability to discontinue the effect mid-cycle. This lack of an 'off switch' is highlighted as a significant safety and tolerability concern.

The speaker claims that the continuous, non-pulsatile GH elevation caused by CJC-1295 DAC leads to desensitization of pituitary receptors over time. As a result, the protocol progressively stops working. This is presented as a direct consequence of eliminating the rest phase that normally preserves receptor sensitivity.

The speaker states that the DAC (Drug Affinity Complex) version of CJC-1295 flatlines growth hormone levels for 6 to 8 days continuously, eliminating the natural pulsatile pattern. This sustained elevation is presented as a fundamental pharmacological distinction from the non-DAC version. No dosage figures are provided, but the once-weekly injection schedule is implied as the common usage pattern being criticized.

The speaker contends there is no practical reason to use CJC-1295 with DAC. If continuous GH elevation is the goal, exogenous growth hormone is preferable because it provides a known, precise dose with decades of clinical data. CJC-1295 with DAC offers neither the pulsatile benefit of a secretagogue nor the dosing precision of exogenous GH.

The speaker argues that the primary rationale for using a GH secretagogue over exogenous GH is to preserve and work with the body's natural pulsatile GH rhythm. CJC-1295 with DAC undermines this rationale by converting pulsatile release into continuous elevation, placing the user in a suboptimal middle ground.

Due to its extended half-life, CJC-1295 with DAC elevates the baseline GH level between natural pulses to approximately 7.5 times above normal. This fills in the valleys between GH pulses, converting the natural pulsatile pattern into a more continuous, flat elevation.

The Drug Affinity Complex (DAC) modification causes CJC-1295 to bind to albumin in the blood, extending its half-life to approximately 7 days. This is the primary pharmacokinetic mechanism distinguishing the DAC variant from the non-DAC version.

The speaker claims, based on their prescribing experience, that patients who correctly execute the pulsatile CJC-1295/Ipamorelin protocol achieve results that users of CJC-1295 DAC are unable to replicate. This is presented as a clinical observation from their practice rather than a controlled study. No specific outcome metrics, dosages, or patient numbers are provided.